Literature DB >> 11920750

A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs.

Shui-Mei Khoo1, Richard J Prankerd, Glenn A Edwards, Christopher J H Porter, William N Charman.   

Abstract

The highly lipid soluble, free-base form of halofantrine (Hf base; approximately 50 mg/mL in triglyceride lipids), a highly lipophilic (calculated log P approximately 8.5) antimalarial, has recently been shown to undergo significant intestinal lymphatic transport (54% of administered dose) after postprandial administration to dogs. In contrast, the clinically available hydrochloride salt of Hf (Hf small middle dot HCl), was not considered to be a likely substrate for lymphatic transport because its solubility in long-chain triglyceride lipids is low (< 1 mg/mL). This paper reports the lymphatic transport of Hf after postprandial administration of Hf.HCl, which was surprisingly high at 47% of the administered dose, and not significantly different from that of Hf base. It was postulated that partial conversion of solubilized Hf.HCl to the highly lipid soluble Hf base within the intestinal lumen might account for the extensive lymphatic transport. However, as Hf is a tertiary amine with an expected pK(a) of > 10, at gastrointestinal pH, the fraction of Hf present as the free base form is likely to be extremely low. Physicochemical studies exploring the solubility and pK(a) of Hf suggest that Hf.HCl was extensively solubilized following fed administration. When solubilized in representative fed state mixed micellar solutions, its apparent pK(a) was 6.92 and considerably lower than anticipated for a tertiary amine. It appears that the extensive lymphatic transport of Hf observed after postprandial administration of Hf.HCl was likely to be due to the conversion of solubilized Hf.HCl to the free base. Therefore, in addition to indicators such as log P and triglyceride solubility, factors such as drug solubilization in representative fed state intestinal conditions and the possible conversion to the un-ionized form should be considered when predicting the potential lymphatic transport of salts of poorly water soluble acids and bases. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:647-659, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920750     DOI: 10.1002/jps.10045

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Exploring the impact of drug properties on the extent of intestinal lymphatic transport - in vitro and in vivo studies.

Authors:  Emma Lawless; Brendan T Griffin; Aoife O'Mahony; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2014-11-27       Impact factor: 4.200

2.  Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.

Authors:  Shui-Mei Khoo; David M Shackleford; Christopher J H Porter; Glenn A Edwards; William N Charman
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 3.  Characterising lipid lipolysis and its implication in lipid-based formulation development.

Authors:  Nicky Thomas; René Holm; Thomas Rades; Anette Müllertz
Journal:  AAPS J       Date:  2012-09-07       Impact factor: 4.009

4.  Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations.

Authors:  Ann Marie Kaukonen; Ben J Boyd; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

5.  Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.

Authors:  Ann Marie Kaukonen; Ben J Boyd; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

6.  Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.

Authors:  Jay Prakash Jain; F Joel Leong; Lan Chen; Sampath Kalluri; Vishal Koradia; Daniel S Stein; Marie-Christine Wolf; Gangadhar Sunkara; Jagannath Kota
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 7.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.